Cochlear Implant in Adults: Indications, Evaluation Process and Rehabilitation

Unlike conventional hearing aids that amplify sound, a cochlear implant is a surgically placed device that directly stimulates the auditory nerve electrically. It can therefore produce hearing perception even when cochlear inner hair cells are essentially absent.

The device has two main parts: an external sound processor worn behind the ear (or in compact off-the-ear, OTE, form factor) — picks up sound via microphones, processes it digitally, and transmits to the internal component via a magnetic coil. The internal component — a receiver/stimulator anchored in the mastoid bone with an electrode array inserted into the cochlea — converts the coded data into electrical pulses that directly excite the auditory nerve fibres.

Modern arrays carry 16-22 active electrodes. Speech-coding strategies (e.g. ACE, HiResolution, FS4) map frequencies onto the cochlea's tonotopic anatomy. The brain learns to interpret these signals over time; thorough rehabilitation is therefore essential.

Hybrid (electroacoustic) implantation: patients with residual low-frequency hearing receive shorter electrodes; low frequencies are delivered acoustically (hearing-aid component), high frequencies electrically. This preserves residual hearing while restoring the high frequencies a hearing aid cannot. Related overview: our otology and hearing centre.

Classical criteria have broadened in recent years. Traditionally, bilateral severe-to-profound sensorineural hearing loss with minimal hearing aid benefit alone was the threshold. Currently accepted expanded criteria:

Audiologic: pure-tone average (500, 1000, 2000, 4000 Hz) ≥70 dB HL in the better ear, AzBio sentence recognition in quiet ≤60% (or CNC word ≤50%), comparable loss in the two ears. Milder loss (PTA 60-70 dB) candidate selection varies by centre. In single-sided deafness (SSD) with normal contralateral hearing, FDA approval (2019) supports implanting the deaf ear.

Imaging: high-resolution temporal bone CT — cochlear anatomy, mastoid aeration, ossification, anomalies (common cavity, IP-II). MRI — cochlear nerve integrity (T2 fat-saturated IAC views), cochlear fluid (labyrinthitis ossificans or scarring), CPA lesions (acoustic neuroma — affects candidacy but not absolute contraindication).

Medical/psychological: active middle/external ear infection must be treated first, uncontrolled seizures, advanced dementia, untreated depression/anxiety, uncontrolled systemic disease. Active meningitis or post-meningitis labyrinthitis ossificans is a special early-implantation indication (before ossification advances).

Aetiology: idiopathic progressive loss, presbycusis, noise-induced loss, ototoxicity (cisplatin, aminoglycosides), genetic (connexin-26 mutations), post-labyrinthitis, otosclerosis, advanced Meniere's, acoustic trauma. Aetiology affects prognosis — long-standing hearing loss requires longer cortical retraining.

Motivation and social support: realistic expectations, willingness to participate in rehabilitation, and a support network matter. Unmotivated patients without follow-through benefit poorly. Pre-implant counselling explores this in detail.

The operation lasts 2-3 hours under general anaesthesia. Classic approach: post-auricular incision, mastoidectomy, posterior tympanotomy (opening bone between facial recess and chorda tympani), and cochleostomy or round window membrane opening to insert the electrode array. The device body sits in a precisely prepared mastoid bone well.

Modern trend: soft surgery — round window approach to preserve residual hearing, with the most atraumatic insertion possible. Robot-assisted and image-guided surgery (3D navigation, intra-op CT) are available in selected centres.

Intra-operative monitoring: neural response telemetry (NRT), impedance measurements, intra-op electrophysiology confirm electrode placement and that nerve stimulation works from the outset. Postoperative CT or plain X-ray confirms electrode position routinely.

Complications: rare but real. Facial nerve injury (<1% in experienced hands), chorda tympani damage (taste change, usually transient), CSF gusher (especially with anatomic anomalies — pre-op MRI important), wound infection, device failure (<5% — revision reimplantation), vertigo (transient), bleeding, clotting. Rarer: meningitis (pneumococcal vaccination is mandatory before implant), electrode migration, incomplete insertion due to cochlear ossification.

Hospital stay: 1-2 days. Recovery in 2 weeks; incision heals during this period. First activation (switch-on) 3-4 weeks postoperatively — after wound healing is complete. More detail: hearing loss page.

First activation: 3-4 weeks postoperatively in the audiologist's office. When the device is switched on, patients may perceive unusual, robotic or unmelodic sounds — the brain is not yet accustomed to the new electrical input. The first session is 60-90 minutes; threshold (T) and maximum comfort (C) levels are measured per electrode. The processor is programmed from these.

First weeks: sound recognition develops gradually. Patients "hear" sounds but need time to interpret them. Word recognition can start at 0%. Soft start and gradual activation help the brain adapt.

First 3 months: most patients' speech recognition improves dramatically. Environmental sounds are differentiated (telephone, doorbell, music). Familiar speakers become intelligible. Mapping updated at 1, 2, 4 and 8 weeks.

Speech therapy/auditory training: leveraging prior hearing aid experience is helpful. Listening therapy (start with simple sentences in quiet, then complex, then with background noise), telephone use training, music listening exercises.

3-6 months: speech understanding in noise, telephone conversation, and multi-talker performance improve. Most patients (70-85%) attain high speech understanding in quiet (sentence 70-90%).

6-12 months and beyond: performance continues to improve. New coding strategies may be tried; bilateral implantation (second ear) is often considered. Yearly follow-up programming — age, outer ear changes, and cochlear neural status require long-term fine-tuning.

Bilateral implantation: small benefit in quiet but significant advantage in noise and spatial hearing (sound localisation). Candidate selection varies by centre and funding.

Adult outcomes are generally good but individual. Typical metrics at 1 year: quiet sentence recognition 70-90%, in-noise 50-70%, word recognition 50-70%. Telephone use and music listening develop individually.

Good prognosis: short duration of deafness (<10 years preferred), pre-implant verbal communication (not writing or sign), good cochlear nerve anatomy, high motivation, education (learning capacity), cognitive integrity.

Poor prognosis: very long (>20 years) deafness, cochlear ossification or neural atrophy, untreated cognitive impairment, low motivation, additional non-auditory nerve damage.

Lifestyle adaptations: water protection of the external processor (modern models IP67/IP68 — swimming, showering possible with accessories), Bluetooth phone and music streaming, air travel (declare the implant at security; passes metal detectors but body scanners may interfere), MRI compatibility (modern implants 1.5T and most 3T; older devices contraindicate MRI), battery management (rechargeable or disposable).

Sport and activity: most sports possible — contact sports (boxing, martial arts) carry head impact risk; swimming with the external processor uses waterproof covers. Deep diving not recommended.

Vaccination: pneumococcal (PCV13 + PPSV23) before implantation is mandatory — reduces postoperative meningitis risk. Annual influenza and routine vaccines standard.

Cost and reimbursement: in Türkiye the social security system covers the implant device and surgery for patients meeting candidacy criteria; private and international insurance coverage varies. Pricing details are evaluated individually during consultation. Related reading: our patient testimonials.